<DOC>
	<DOCNO>NCT02352792</DOCNO>
	<brief_summary>Patients locally advance suqamous cell carcinoma head neck region receive hypoxia scan either magnetic resonance tomography , compute tomography fluoromisonidazole ( FMISO ) -PET-CT . Patients present hypoxia randomize standard therapy consist intensity modulate radiotherapy ( IMRT ) 70 Gy plus either 5-fluorouracil/mitomycin C cisplatinum ( Arm A ) dose escalation 10 % ( 77Gy ) hypoxic volume apply via simultaneous integrate boost addition standard treatment ( Arm B ) .</brief_summary>
	<brief_title>Hypoxia-based Dose Escalation With Radiochemotherapy Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>histologically verify squamous cell carcinoma head neck region stage III IV eligible primary radiochemotherapy measurabel disease CT and/or MRT and/or FDGPETCT fit chemotherapy prior radiotherapy major surgery head/neck region Karnofsky Index &gt; 60 % informed consent uncontrolled secondary cancer distant metastases pregnancy expect malcompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Local control</keyword>
</DOC>